Novartis Sues Ranbaxy Over Top-Selling Diovan

Law360, New York (August 13, 2007, 12:00 AM EDT) -- Novartis International AG has sued Ranbaxy Laboratories Limited, looking to stave off generic competition in the multibillion dollar market for the hypertension treatment Diovan, which Novartis touts as the world's leading branded high blood pressure medication.

Novartis filed its lawsuit Thursday in New Jersey against New Delhi, India-based Ranbaxy and one of its U.S. subsidiaries, accusing the defendants of infringing a single patent covering Diovan, which contains the active ingredient valsartan.

Diovan is Novartis' top-selling drug, according to the company's sales figures for the first half...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.